Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.
about
Epidemiology of Alzheimer diseaseTaurine in drinking water recovers learning and memory in the adult APP/PS1 mouse model of Alzheimer's diseaseHuman neural stem cells alleviate Alzheimer-like pathology in a mouse model.Chronic treatment with anesthetic propofol improves cognitive function and attenuates caspase activation in both aged and Alzheimer's disease transgenic miceAcetylcholinesterase inhibitor modifications: a promising strategy to delay the progression of Alzheimer's disease.Deciphering Alzheimer disease.Guest editorial: Opportunities in rehabilitation research.Matrine improves cognitive impairment and modulates the balance of Th17/Treg cytokines in a rat model of Aβ1-42-induced Alzheimer's diseasePrevention approaches in a preclinical canine model of Alzheimer's disease: benefits and challenges.Alzheimer disease in 2020.Combination of Aβ clearance and neurotrophic factors as a potential treatment for Alzheimer's disease.Alzheimer's disease drug development: translational neuroscience strategies.Use of genetically modified mesenchymal stem cells to treat neurodegenerative diseases.Lavandula angustifolia extract improves deteriorated synaptic plasticity in an animal model of Alzheimer's disease.Natural sesquiterpen lactones as acetylcholinesterase inhibitors.Is there a causal link between inflammation and dementia?Tanshinone IIA Alleviates the AD Phenotypes in APP and PS1 Transgenic Mice.Markers of Alzheimer's Disease in Primary Visual Cortex in Normal Aging in Mice.Recent Progress in the Pharmacotherapy of Alzheimer's Disease.
P2860
Q26865371-C5B27251-0129-48CD-B8F0-66099BC98E10Q28649926-395F8FBF-E657-458F-947B-413F1FB7313CQ30662068-D97B4CD6-2500-4439-87F5-1F1ABC6A5EC7Q33807350-0ED67B24-1AC1-428F-B6AC-E8190B78DF73Q35169922-1BB2A2B6-3A44-48E1-964A-F510B92AA26BQ35658189-9E5AFC86-CDA0-473E-9F8C-BAC5F3B173DBQ36142473-F626D7E3-DB62-4E3E-ADBA-4FE4B3A7DDCBQ36534248-E3DBBD0E-51EB-4A7A-AEA1-7B227D8F5F5CQ37670716-67CEB936-E0DF-4F65-A6DE-A87F18D536E2Q38057724-12FDB40E-84A7-4949-9374-B571A973B7F2Q38062334-2894BB96-4C76-47AC-8997-A2A37C2FA3BCQ38087640-FA93853C-4113-477E-B1B2-0AC0B8970ED9Q38181868-790F47E6-61AD-4CBF-9E1A-7D03136F91B7Q38600851-0618F0FE-4BF5-4882-A7CA-E3F3AC6DC3DCQ39190468-54A855F4-6FFD-4B0C-A702-84779820300BQ39387457-6402306D-4E94-4DBB-9AEA-1BFE81ADB6CCQ42254304-3E2CBDA4-8999-48EA-81DE-74EBAD732C76Q43375858-0EB54A16-2C29-4155-9B22-76F49E5EAF61Q47425364-D1384D77-F595-43C7-9EA4-2E4A8C26BFED
P2860
Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.
@ast
Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.
@en
type
label
Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.
@ast
Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.
@en
prefLabel
Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.
@ast
Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.
@en
P2860
P1476
Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.
@en
P2093
Lon S Schneider
P2860
P304
P356
10.1101/CSHPERSPECT.A006395
P577
2012-03-01T00:00:00Z